Design Therapeutics, Inc. (DSGN) Cash Flow Statement
Design Therapeutics, Inc. (DSGN) generated -$55.1M of operating cash flow over the twelve months to 2026-06-30, spent $55000 on capital expenditure and had free cash flow of -$55.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DSGNDesign Therapeutics, Inc.Follow DSGN — free
—
Price chart with a free account
- Market cap
- 640.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -29.4 | -51.3 | -58.6 | -43.1 | -54.4 | -55.1 | |
| Capital expenditure | 1.5 | 0.9 | 0.3 | 0.3 | 0.2 | -0.1 | |
| Free cash flow | -30.9 | -52.2 | -58.8 | -43.4 | -54.6 | -55.1 | |
| Stock-based compensation | 4.7 | 10.9 | 13.1 | 13.1 | 14.5 | — |
USD millions · SEC XBRL
Design Therapeutics, Inc. — questions
- What is Design Therapeutics, Inc.'s operating cash flow?
- -$55.1M over the twelve months to 2026-06-30.
- How much does Design Therapeutics, Inc. spend on capital expenditure?
- $55000 over the twelve months to 2026-06-30.
- What is Design Therapeutics, Inc.'s free cash flow?
- -$55.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Design Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.